Cyclacel hosts Research and Development Day

BERKELEY HEIGHTSCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP; ‘cyclacel‘ or the ‘Company’), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has hosted a Key Opinion Leaders (KOL) Research and Development Day focused on the Company’s CDK2/9 inhibitor , oral fadraciclib and PLK1 inhibitor, oral CYC140 Monday 31 October 2022 at 10:00 a.m. Eastern Time.

The R&D day will feature renowned KOLs in oncology and program updates from senior management.

Jasmine ZainMD, from City of Hope National Medical Centerprovides an overview of the unmet medical need in the treatment of T-cell lymphoma.

Do-youn ohMD, PhD, from Seoul National Universitywill discuss unmet medical needs and current treatment options for hepatobiliary cancers.

That cyclacel The executive team will then provide a program update on the Company’s pipeline, highlighting patient data from the Phase 1/2 065-101 study of oral fadraciclib in solid tumors and lymphoma. In addition, an update will address progress with CYC140, cyclacels oral PLK1 inhibitor, in a phase 1/2 study as a potential treatment for solid tumors and lymphoma.

dr zain is a professor at Department of Hematology and Hematopoietic Cell Transplantation and since 2014 director of the T-cell lymphoma program at the Toni Stephenson Lymphoma Center in City of Hope. She has directed many clinical trials on T-cell lymphoma and is a member of the NCCN Guideline Committee for the Treatment of T-cell Lymphoma.

dr zain earned her medical degree Fatima Jinnah Medical College for women in Lahore, Pakistan. She then completed an internship and residency at North Shore Hospital, Forest Hill, New Yorkfollowed by a fellowship in hematology/oncology New York University Medical Center. During her career she has worked at many institutions including University of Columbia and NYU Medical Center. Her focus remains on the development of novel therapies for T-cell lymphomas.

Triple board certified in hematology, oncology and internal medicine, dr zain is an active member of several professional organizations and has published more than 78 peer-reviewed publications, abstracts and book chapters. She has been invited to speak both nationally and internationally.

dr Oh is a professor Department of Medical Oncology, Department of Internal Medicine at Seoul National University and Seoul National University College of Medicine.

dr Oh completed Seoul National University College of Medicine in 1997 and had a residency in internal medicine and a fellowship in hematology/medical oncology training at the Seoul National University Hospital. She received her doctorate in the Department of Internal Medicine In the Seoul National University College of Medicine in the year 2005.

Her main research interests include gastric, pancreatic and bile duct cancer, with a particular interest in translational research and early drug development. She has published over 250 peer-reviewed journal articles and serves on numerous committees, including the Korean Cancer Association, Korean Clinical Oncology Association, Korean Cancer Study Group, American Society for Clinical Oncologyand American Association for Research on Cancer.

Around Cyclacel Pharmaceuticals, Inc.

cyclacel is a clinical-stage biopharmaceutical company developing innovative anticancer drugs based on the cell cycle, transcriptional regulation and mitotic biology. The transcription regulation program is evaluating Fadraciclib, a CDK2/9 inhibitor, and the antimitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. cyclacels The strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates in oncology and hematology indications.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding the efficacy, safety and intended use of cyclacels Product candidates, the conduct and results of future clinical trials, plans for regulatory filings, future research and clinical trials, and plans for partnering activities. Factors that could cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical studies may not demonstrate safety and/or efficacy in larger or later clinical studies may have difficulty recording cyclacel may not receive approval to commercialize its product candidates, the risks associated with reliance on outside funding to meet capital requirements, the potential impact of the COVID-19 pandemic and the risks associated with reliance on collaborators for further clinical trials, development and commercialization of product candidates. You are urged to consider statements containing the words “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”. “Plans”, “anticipates”, “intends”, “continues”, “forecast”, “designed”, “goal” or the negative of these words or other comparable words as uncertain and forward-looking. A further list and description of the risks and uncertainties faced by the Company can be found in our most recent Annual Report on Form 10-K and other periodic and other filings that we file with Securities and Exchange Commission and are available at Such forward-looking statements speak only as of the date made, and we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.


Paul McBarron

Tel: (908) 517-7330

Email: [email protected]

Comments are closed.